Rapamycin enhances dimethyl sulfoxide-mediated growth arrest in human myelogenous leukemia cells

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2253-2261

  Lalic, Hrvoje ^a   Lukinovic Skudar, Vesna ^a   Banfic, Hrvoje ^a   Visnjic, Dora ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

dimethyl sulfoxide; leukemia; Rapamycin

Indexed keywords

CD11B ANTIGEN; DIMETHYL SULFOXIDE; RAPAMYCIN; RETINOIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN K 562; CELL STRAIN U937; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; G2 PHASE CELL CYCLE CHECKPOINT; LEUKEMIA CELL; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

CELL PROLIFERATION; DIMETHYL SULFOXIDE; DRUG SYNERGISM; HL-60 CELLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 84867177893     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.684351     Document Type: Article

References (31)

1. Altman JK, Sassano A, Platanias LC. Targeting mTOR for the treatment of AML. New agents and new directions. Oncotarget 2011; 2:510-517.
2. Martelli AM, Evangelisti C, Chappell W, et al. Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway. Leukemia 2011;25:1064-1079.
3. Sengupta S, Peterson TR, Sabatini DM. Regulation of mTOR complex 1 pathway by nutrients, growth factors, and stress. Mol Cell 2010;40:310-322.
4. Xu Q, Simpson SE, Scialla TJ, et al. Survival of acute myeloid leukemia cells requires PI3 kinase activation. Blood 2003;102:972-980. (Pubitemid 36917792)
5. Récher C, Beyne-Rauzy O, Demur C, et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005;105:2527-2534. (Pubitemid 40387055)
6. Tamburini J, Green AS, Bardet V, et al. Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. Blood 2009;114:1618-1627.
7. Hagner PR, Schneider A, Gartenhaus RB. Targeting the translational machinery as a novel treatment strategy for hematologic malignancies. Blood 2010;115:2127-2135.
8. Petrie K, Zelent A, Waxman S. Dif erentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 2009; 16:84-91.
9. Ketley NJ, Allen PD, Kelsey SM, et al. Mechanisms of resistance to apoptosis in human AML blasts: the role of dif erentiation-induced perturbations of cell-cycle checkpoints. Leukemia 2000;14:620-628. (Pubitemid 30195452)
10. Trus MR, Yang L, Suarez Saiz F, et al. The histone deacetylase inhibitor valproic acid alters sensitivity towards all trans retinoic acid in acute myeloblastic leukemia cells. Leukemia 2005;19:1161-1168. (Pubitemid 40945999)
11. Nishioka C, Ikezoe T, Yang J, et al. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and dif erentiation of human acute myelogenous leukemia cells. Int J Cancer 2009;125:1710-1720.
12. 3 to induce growth arrest and dif erentiation of AML cells in vitro and in vivo. Exp Hematol 2010;38:666-676.
13. Friend C, Scher W, Holland JG, et al. Hemoglobin synthesis in murine virus-induced leukemic cells in vitro : stimulation of erythroid dif erentiation by dimethyl sulfoxide. Proc Natl Acad Sci USA 1971; 68:378-382.
14. Monczak Y, Trudel M, Lamph WW, et al. Induction of apoptosis without dif erentiation by retinoic acid in PLB-985 cells requires the activation of both RAR and RXR. Blood 1997;90:3345-3355. (Pubitemid 27473402)
15. Kanayasu-Toyoda T, Yamaguchi T, Oshizawa T, et al. Role of the p70 S6 kinase cascade in neutrophilic dif erentiation and proliferation of HL-60 cells-a study of transferrin receptor-positive and-negative cells obtained from dimethyl sulfoxide-or retinoic acid-treated HL-60 cells. Arch Biochem Biophys 2002;405:21-31. (Pubitemid 35026162)
16. Vondráček J, Souček K, Sheard MA, et al. Dimethyl sulfoxide potentiates death receptor-mediated apoptosis in the human myeloid leukemia U937 cell line through enhancement of mitochondrial membrane depolarization. Leuk Res 2006;30:81-89. (Pubitemid 41654709)
17. Bruecher-Encke B, Grif n JD, Neel BG, et al. Role of the tyrosine phosphatase SHP-1 in K562 cell dif erentiation. Leukemia 2001;15:1424-1432. (Pubitemid 32785312)
18. Matkovic K, Brugnoli F, Bertagnolo V, et al. The role of the nuclear Akt activation and Akt inhibitors in all-trans-retinoic acid-dif erentiated HL-60 cells. Leukemia 2006;20:941-951. (Pubitemid 43797283)
19. Mise J, Dembitz V, Banf c H, et al. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative ef ect, but diminishes dif erentiative properties of rapamycin in acute myeloid leukemia cells. Pathol Oncol Res 2011;17:645-656.
20. Wall M, Poortinga G, Hannan KM, et al. Translational control of c-MYC by rapamycin promotes terminal myeloid dif erentiation. Blood 2008;112:2305-2317.
21. Yamamoto-Yamaguchi Y, Okabe-Kado J, Kasukabe T, et al. Induction of dif erentiation of human myeloid leukemia cells by immunosuppressant macrolides (rapamycin and FK506) and calcium/calmodulin-dependent kinase inhibitors. Exp Hematol 2001;29:582-588. (Pubitemid 32463894)
22. Isakson P, Bjørås M, Bøe SO, et al. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein. Blood 2010;116:2324-2331.
23. Billottet C, Banerjee L, Vanhaesebroeck B, et al. Inibition of class I phosphoinositide 3-kinase activity impairs proliferation and triggers apoptosis in acute promyelocytic leukemia without af ecting Atra-induced dif erentiation. Cancer Res 2009;69:1027-1036.
24. Gomez-Cambronero J, Frye T, Baumann M. Ribosomal p70S6K basal activity increases upon induction of dif erentiation of myelo-monocytic leukemic cell lines HL60, AML14 and MPD. Leuk Res 2004; 28:755-762. (Pubitemid 38639743)
25. Lal L, Li Y, Smith J, et al. Activation of the p70S6K kinase by all-trans-retinoic acid in acute promyelocytic leukemia cells. Blood 2005;105;1669-1677. (Pubitemid 40223689)
26. Clarke CJ, Mediwala K, Jenkins RW, et al. Neutral sphingo-myelinase-2 mediates growth arrest by retinoic acid through modulation of ribosomal S6 kinase. J Biol Chem 2011;286:21565-21576.
27. Parmar S, Smith J, Sassano A, et al. Dif erential regulation of the p70 S6 kinase pathway by interferon α (IFNα ) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells. Blood 2005; 106:2436-2443. (Pubitemid 41510818)
28. Zhu Q, Zhang JW, Zhu HQ, et al. Synergic effects of arsenic trioxide and cAMP during acute promyelocytic leukemia cell maturation subtends a novel signaling cross-talk. Blood 2002;99:1014-1022. (Pubitemid 34525566)
29. Vondráček J, Sheard MA, Krejči P, et al. Modulation of death receptor-mediated apoptosis in dif erentiating human myeloid leukemia HL-60 cells. J Leukoc Biol 2001;69:794-802. (Pubitemid 32466419)
30. Hu Y, Yao J, Liu Z, et al. Akt phosphorylates acinus and inhibits its proteolytic cleavage, preventing chromatin condensation. EMBO J 2005;24:3543-3554. (Pubitemid 41509362)
31. Neri LM, Marchisio M, Colamussi ML, et al. Monocytic dif erentiation of HL-60 cells is characterized by the nuclear translocation of phosphatidylinositol 3-kinase and of def nite phosphatidylinositol-specif c phospholipase C isoforms. Biochem Biophys Res Commun 1999;259:314-320. (Pubitemid 29281228)